Progressive Pulmonary Fibrosis: Should the Timelines Be Taken Out of the Definition?

por Cottin, Vincent, Brown, Kevin K., Flaherty, Kevin R., Wells, Athol U.
Publicado 2022

Acute exacerbation of chronic bronchitis: disease-specific issues that influence the cost-effectiveness of antimicrobial therapy

por Saint, Sanjay, Flaherty, Kevin R., Abrahamse, Paul, Martinez, Fernando J., Fendrick, A.Mark
Publicado 2001

Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis: Experience from 92 Sites in an Open-Label US Expanded Access Program

por Lancaster, Lisa, Morrison, Lake, Auais, Alexander, Ding, Beiying, Iqbal, Ahmar, Polman, Boris, Flaherty, Kevin R.
Publicado 2017

B7H3-dependent myeloid-derived suppressor cell recruitment and activation in pulmonary fibrosis

por Liu, Tianju, Gonzalez De Los Santos, Francina, Rinke, Andrew E., Fang, Chuling, Flaherty, Kevin R., Phan, Sem H.
Publicado 2022

Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics

por Kolb, Martin, Flaherty, Kevin R., Silva, Rafael S., Prasse, Antje, Vancheri, Carlo, Mueller, Heiko, Sroka-Saidi, Kamila, Wells, Athol U.
Publicado 2023

Inflammatory Leukocyte Phenotypes Correlate with Disease Progression in Idiopathic Pulmonary Fibrosis

por Moore, Bethany B., Fry, Chris, Zhou, Yueren, Murray, Susan, Han, MeiLan K., Martinez, Fernando J., Flaherty, Kevin R.
Publicado 2014

Which Biopsy to Diagnose Interstitial Lung Disease? A Call for Evidence and Unity

por Richeldi, Luca, Cottin, Vincent, Brown, Kevin K., Flaherty, Kevin R., Johannson, Kerri A., Travis, William D., Collard, Harold R.
Publicado 2019

The characterisation of interstitial lung disease multidisciplinary team meetings: a global study

por Richeldi, Luca, Launders, Naomi, Martinez, Fernando, Walsh, Simon L.F., Myers, Jeffrey, Wang, Bonnie, Jones, Mark, Chisholm, Alison, Flaherty, Kevin R.
Publicado 2019

Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonar...

por Holtze, Colin H., Freiheit, Elizabeth A., Limb, Susan L., Stauffer, John L., Raimundo, Karina, Pan, Wayne T., Flaherty, Kevin R., Kim, Hyun J.
Publicado 2020

Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis

por Nathan, Steven D, Behr, Jurgen, Cottin, Vincent, Lancaster, Lisa, Smith, Peter, Deng, CQ, Pearce, Natalie, Bell, Heidi, Peterson, Leigh, Flaherty, Kevin R
Publicado 2022

Six-SOMAmer Index Relating to Immune, Protease and Angiogenic Functions Predicts Progression in IPF

por Ashley, Shanna L., Xia, Meng, Murray, Susan, O’Dwyer, David N., Grant, Ethan, White, Eric S., Flaherty, Kevin R., Martinez, Fernando J., Moore, Bethany B.
Publicado 2016

External validation and longitudinal application of the DO-GAP index to individualise survival prediction in idiopathic pulmonary fibrosis

por Chandel, Abhimanyu, King, Christopher S., Ignacio, Rosalinda V., Pastre, Jean, Shlobin, Oksana A., Khangoora, Vikramjit, Aryal, Shambhu, Nyquist, Alan, Singhal, Anju, Flaherty, Kevin R., Nathan, Steven D.
Publicado 2023

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis

por Flaherty, Kevin R., Fell, Charlene D., Huggins, J. Terrill, Nunes, Hilario, Sussman, Robert, Valenzuela, Claudia, Petzinger, Ute, Stauffer, John L., Gilberg, Frank, Bengus, Monica, Wijsenbeek, Marlies
Publicado 2018

Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial

por Podolanczuk, Anna J., Kim, John S., Cooper, Christopher B., Lasky, Joseph A., Murray, Susan, Oldham, Justin M., Raghu, Ganesh, Flaherty, Kevin R., Spino, Cathie, Noth, Imre, Martinez, Fernando J.
Publicado 2022

Factors associated with listing for lung transplantation in IPF patients: An analysis of the pulmonary fibrosis foundation registry

por King, Christopher S., White, Emily, Aryal, Shambhu, Shlobin, Oksana A., Singhal, Anju, Brown, A. Whitney, Thomas, Christopher, Khangoora, Vikramjit, Nyquist, Alan, Flaherty, Kevin R., Nathan, Steven D., Mooney, Joshua J.
Publicado 2023

A Micro RNA Processing Defect in Rapidly Progressing Idiopathic Pulmonary Fibrosis

por Oak, Sameer R., Murray, Lynne, Herath, Athula, Sleeman, Matthew, Anderson, Ian, Joshi, Amrita D., Coelho, Ana Lucia, Flaherty, Kevin R., Toews, Galen B., Knight, Darryl, Martinez, Fernando J., Hogaboam, Cory M.
Publicado 2011

Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry

por Snyder, Laurie D, Mosher, Christopher, Holtze, Colin H, Lancaster, Lisa H, Flaherty, Kevin R, Noth, Imre, Neely, Megan L, Hellkamp, Anne S, Bender, Shaun, Conoscenti, Craig S, de Andrade, Joao A, Whelan, Timothy PM
Publicado 2020

Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Del...

por Rahaghi, Franck F., Safdar, Zeenat, Brown, Anne Whitney, de Andrade, Joao A., Flaherty, Kevin R., Kaner, Robert J., King, Christopher S., Padilla, Maria L., Noth, Imre, Scholand, Mary Beth, Shifren, Adrian, Nathan, Steven D.
Publicado 2020

Nintedanib in children and adolescents with fibrosing interstitial lung diseases

por Deterding, Robin, Young, Lisa R., DeBoer, Emily M., Warburton, David, Cunningham, Steven, Schwerk, Nicolaus, Flaherty, Kevin R., Brown, Kevin K., Dumistracel, Mihaela, Erhardt, Elvira, Bertulis, Julia, Gahlemann, Martina, Stowasser, Susanne, Griese, Matthias
Publicado 2023

Patient Registries in Idiopathic Pulmonary Fibrosis

por Culver, Daniel A., Behr, Jürgen, Belperio, John A., Corte, Tamera J., de Andrade, Joao A., Flaherty, Kevin R., Gulati, Mridu, Huie, Tristan J., Lancaster, Lisa H., Roman, Jesse, Ryerson, Christopher J., Kim, Hyun J.
Publicado 2019